Eledon Pharmaceuticals Current Ratio Growth & History (ELDN)
Eledon Pharmaceuticals's current ratio was 7.40 for fiscal 2025.
View full Eledon Pharmaceuticals company overviewEledon Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.40 | −5.02 | −40.42% |
| 2024 | 2024-12-31 | 12.42 | −2.00 | −13.85% |
| 2023 | 2023-12-31 | 14.41 | 5.22 | +56.77% |
| 2022 | 2022-12-31 | 9.19 | −10.88 | −54.21% |
| 2021 | 2021-12-31 | 20.07 | −26.49 | −56.89% |
| 2020 | 2020-12-31 | 46.57 | 39.03 | +517.43% |
| 2019 | 2019-12-31 | 7.54 | 1.91 | +33.88% |
| 2018 | 2018-12-31 | 5.63 | — | — |
| 2016 | 2016-12-31 | 0.30 | −10.61 | −97.29% |
| 2015 | 2015-12-31 | 10.90 | −14.44 | −56.98% |
| 2014 | 2014-12-31 | 25.34 | 10.77 | +73.95% |
| 2013 | 2013-12-31 | 14.57 | — | — |
Eledon Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 7.90 | −0.22 | −2.76% |
| Q1 2026 | 2026-03-31 | 8.44 | −5.47 | −39.31% |
| Q4 2025 | 2025-12-31 | 7.40 | −5.02 | −40.42% |
| Q3 2025 | 2025-09-30 | 6.74 | 0.21 | +3.21% |
| Q2 2025 | 2025-06-30 | 8.12 | −6.36 | −43.91% |
| Q1 2025 | 2025-03-31 | 13.91 | 2.61 | +23.09% |
| Q4 2024 | 2024-12-31 | 12.42 | −2.00 | −13.85% |
| Q3 2024 | 2024-09-30 | 6.53 | −15.20 | −69.96% |
| Q2 2024 | 2024-06-30 | 14.48 | −0.55 | −3.65% |
| Q1 2024 | 2024-03-31 | 11.30 | 2.37 | +26.54% |
| Q4 2023 | 2023-12-31 | 14.41 | 5.22 | +56.77% |
| Q3 2023 | 2023-09-30 | 21.73 | 10.97 | +101.96% |
| Q2 2023 | 2023-06-30 | 15.02 | −7.19 | −32.38% |
| Q1 2023 | 2023-03-31 | 8.93 | −17.89 | −66.71% |
| Q4 2022 | 2022-12-31 | 9.19 | −10.88 | −54.21% |
| Q3 2022 | 2022-09-30 | 10.76 | −12.86 | −54.45% |
| Q2 2022 | 2022-06-30 | 22.22 | −16.10 | −42.02% |
| Q1 2022 | 2022-03-31 | 26.82 | 0.61 | +2.31% |
| Q4 2021 | 2021-12-31 | 20.07 | −26.49 | −56.89% |
| Q3 2021 | 2021-09-30 | 23.62 | 4.84 | +25.78% |
| Q2 2021 | 2021-06-30 | 38.32 | 29.42 | +330.66% |
| Q1 2021 | 2021-03-31 | 26.21 | 19.36 | +282.38% |
| Q4 2020 | 2020-12-31 | 46.57 | 39.03 | +517.43% |
| Q3 2020 | 2020-09-30 | 18.78 | 11.37 | +153.64% |
| Q2 2020 | 2020-06-30 | 8.90 | 1.10 | +14.18% |
| Q1 2020 | 2020-03-31 | 6.85 | 3.67 | +115.25% |
| Q4 2019 | 2019-12-31 | 7.54 | 1.91 | +33.88% |
| Q3 2019 | 2019-09-30 | 7.40 | — | — |
| Q2 2019 | 2019-06-30 | 7.79 | — | — |
| Q1 2019 | 2019-03-31 | 3.18 | — | — |
| Q4 2018 | 2018-12-31 | 5.63 | — | — |
| Q3 2017 | 2017-09-30 | 9.12 | 3.39 | +59.27% |
| Q2 2017 | 2017-06-30 | 7.86 | 1.95 | +33.06% |
| Q1 2017 | 2017-03-31 | 10.60 | 1.37 | +14.85% |
| Q4 2016 | 2016-12-31 | 0.30 | −10.61 | −97.29% |
| Q3 2016 | 2016-09-30 | 5.73 | −7.86 | −57.85% |
| Q2 2016 | 2016-06-30 | 5.91 | −12.76 | −68.35% |
| Q1 2016 | 2016-03-31 | 9.23 | −7.52 | −44.89% |
| Q4 2015 | 2015-12-31 | 10.90 | −14.44 | −56.98% |
| Q3 2015 | 2015-09-30 | 13.59 | −6.28 | −31.61% |
| Q2 2015 | 2015-06-30 | 18.67 | — | — |
| Q1 2015 | 2015-03-31 | 16.74 | — | — |
| Q4 2014 | 2014-12-31 | 25.34 | 10.77 | +73.95% |
| Q3 2014 | 2014-09-30 | 19.87 | — | — |
| Q4 2013 | 2013-12-31 | 14.57 | — | — |
Eledon Pharmaceuticals current ratio trends
Over the last five fiscal years, Eledon Pharmaceuticals's current ratio decreased from 46.57 to 7.40, a change of −39.17. The latest reported quarter, Q2 2026, shows 7.90.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eledon Pharmaceuticals source filings ↗